Solid phase sandwich ELISA for the determination human APP770 in EDTA-plasma, cerebrospinal fluid and cell culture supernatant. For research use only, not for use in diagnostic procedures.<br><br>
Alzheimer's disease (AD) is a typical senile dementia and it is believed that accumulation of Amyloidβ (Aβ) in brain parenchyma is a major cause of the disease. Meanwhile, accumulation of Aβ has been also observed on cerebrovascular walls of nearly 90% of individuals suffering with AD. Aβ is known to be produced from Amyloid Precursor Protein (APP) by cleavage with two types of protease (β- and γ- secretase) and Aβ molecules which accumulate in brain parenchyma are mainly produced from APP expressed in neurons, APP695. In contrast to this, another different APP, APP770, was found to be expressed in cerebrovascular endothelial cells, and it has been newly reported that the Aβ produced from the APP770 can accumulate on cerebrovascular walls. This ELISA kit can measure human APP770 in EDTA-plasma, cerebrospinal fluid and cell culture supernatant.
- Assay Description:
- Overnight incubation (4°C) + 30 min. (4°C) + 30 min. (RT) = Overnight + 1 hour total incubation time
- Catalog number:
- 27736
- configuration:
- 96 Determinations, 12x8 removable strips
- controls:
- None provided
- design:
- Solid phase sandwich ELISA using 2 kinds of highly specific antibodies
- FDA Status:
- For research use only, not for use in diagnostic procedures
- MSDS:
- notes:
- The protocol for this product (see above) is intended to serve as an example only. Please refer to the Instructions For Use provided with the assay kit for precise details.
- Protocol:
- Sample types:
- EDTA-plasma, ceribrospinal fluid and cell culture supernatant
- Sample volume:
- 100 μL of properly diluted unknown / determination
- standards:
- 8 standards, serially diluted from 1 prepared lyophilized standard
- Standard range:
- 0 / 0.10 - 6.2 ng/mL
- storage:
- 2 - 8°C
- sensitivity:
- 0.03 ng/mL
- Species:
- Human
- Additional info:
- References:
